Generally speaking, the median PFS of advanced lung adenocarcinoma treated with an EGFR TKI is about 9–13 months as shown in several phase III randomized controlled trials.4, 5, 6, 7, 8, 9, 10, 11. Here, EGFR is linked to lung adenocarcinoma.